Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

August’s top stories: Bayer, Compugen partner for cancer immunotherapy

Bayer and Compugen have formed a strategic alliance to develop a new cancer treatment, Novartis's Afinitor Phase III trial failed to meet its primary end-point and A*STAR's GIS researchers discovered neurogenesis controlling long non-coding RNA. Drugdevelopment-technology.com wraps up key headlines from August 2013.

Go Top